ARQT
Arcutis BiotherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The cleanest bull case is that Arcutis is transitioning from biotech to scaled dermatology commercial company: ZORYVE revenue grew 65% year over year in Q1, the company sustained positive operating cash flow, maintained $480M-$495M 2026 revenue guidance, and has now added another pediatric label expansion to deepen franchise breadth [#PR-EARNINGS-2026-05-07] [#IR-2026-06-29].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -4.6.
What can break
Commercial investment is still elevated: Q1 SG&A rose year over year due to compensation, personnel, and higher sales and marketing spending tied to ongoing launch expansion [#PR-EARNINGS-2026-05-07].
Momentum
84
Value
49
Sentiment
42
Setup hits (3d)
— · Net —
AI TargetsBase $28.00 · Bull $34.00 · Bear $20.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-30 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net —
Target $34.63
Why
Momentum84 · Δ7d -4.6
Value49 · Δ7d -0.1
Sentiment42 · Δ7d -5.7
So what
Strength-led posture. Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
84
26% active weight
Current posture
7d trendFlat
Δ7d
-4.6
Δ21d
-5.9
Value
49
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.1
Sentiment
42
34% active weight
Current posture
7d trendSoftening
Δ7d
-5.7
Δ21d
-18.8
Why this grade
Composite grade B. Momentum 83.8 / Value 48.7 / Sentiment 41.9
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$3.56B
Beta
1.71
Shares Out
125.08M
P/E (TTM) · Derived
-224.5
P/S (TTM)
11.64
P/FCF (TTM) · Derived
143.09
Rev YoY
+60.1%
EPS YoY
-56.1%
Gross Margin
+90.9%
Op Margin
-12.0%
Net Debt
-$107.07M
Current Ratio
2.68
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology